| pubmed-article:15922721 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C0567416 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C0699040 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C0023828 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C1335808 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C1145667 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:15922721 | lifeskim:mentions | umls-concept:C1611341 | lld:lifeskim |
| pubmed-article:15922721 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:15922721 | pubmed:dateCreated | 2005-5-30 | lld:pubmed |
| pubmed-article:15922721 | pubmed:abstractText | We previously reported that synthetic sulfo-glycolipid, 3-O-(6-deoxy-6-sulfono-beta-D-glucopyranosyl)-1,2-di-O-acylglycerol (beta-SQDG(18:0)) which was deduced from sulfonoquinovosyl-diacylglycerols of sea urchin possessed immunosuppressive effects, such as human mixed lymphocyte reaction (MLR) and skin allograft in rat, and that these effects were caused by contact inhibition between T-cells and antigen presenting cells (APCs). Here, we investigated the mechanism of these immunosuppressive effects on human MLR by beta-SQAG9 which had been newly synthesized from beta-SQDG(18:0) to improve structural stability in water solution. CD62L+ T-cells in peripheral blood predominantly respond to APCs, and beta-SQAG9 inhibited the response of CD62L+ T-cell subset in human allogeneic MLR. Surprisingly, it was demonstrated that beta-SQAG9 bound to L- and P-selectin (CD62L and P) molecule in vitro. Meanwhile, beta-SQAG9 efficiently formed liposome structure and bound to L-selectin on the cell surface of CD62L+ T-cell subset but might not be incorporated into the cells. Because the immunosuppressive effects of beta-SQAG9 disappeared when beta-SQAG9 liposome was changed to soluble form by detergent, the liposome structure of beta-SQAG9 was presumed to be essential for these effects. These findings suggested beta-SQAG9 to be a novel drug with a unique immunosuppressive action. | lld:pubmed |
| pubmed-article:15922721 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15922721 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15922721 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15922721 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15922721 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15922721 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15922721 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15922721 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15922721 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15922721 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15922721 | pubmed:issn | 0008-8749 | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:SugawaraFumio... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:SakaguchiKeng... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:SatoNoriyukiN | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:SaharaHiroeki... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:OhtaKeisukeK | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:GasaShinseiS | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:TakahashiNobu... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:MatsumotoKenj... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:MatsumotoYosh... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:FujitaTatsuya... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:TakenouchiMik... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:JimbowKowichi... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:TamuraYasuaki... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:YamamotoYoshi... | lld:pubmed |
| pubmed-article:15922721 | pubmed:author | pubmed-author:ImaiAkihitoA | lld:pubmed |
| pubmed-article:15922721 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15922721 | pubmed:volume | 232 | lld:pubmed |
| pubmed-article:15922721 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15922721 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15922721 | pubmed:pagination | 105-15 | lld:pubmed |
| pubmed-article:15922721 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:meshHeading | pubmed-meshheading:15922721... | lld:pubmed |
| pubmed-article:15922721 | pubmed:articleTitle | Inhibition of CD62L+ T-cell response in vitro via a novel sulfo-glycolipid, beta-SQAG9 liposome that binds to CD62L molecule on the cell surface. | lld:pubmed |
| pubmed-article:15922721 | pubmed:affiliation | Division of Plastic Surgery, Sapporo Medical University School of Medicine, South 1 West 17, Chuo-ku, Sapporo 060-8556, Japan. | lld:pubmed |
| pubmed-article:15922721 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15922721 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
